Castro Cabezas M, Erkelens D W, Kock L A, De Bruin T W
Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.
Eur J Clin Invest. 1994 Oct;24(10):669-78. doi: 10.1111/j.1365-2362.1994.tb01059.x.
Hepatic VLDL overproduction in familial combined hyperlipidaemia (FCH) may delay the clearance of atherogenic apolipoprotein (apo) B containing particles. We investigated if normalization of fasting plasma triglycerides (TG) by hypolipidaemic treatment results in improved metabolism of apo B48 and apo B100 in six male subjects with FCH and compared them to six normolipidaemic controls. The FCH patients were studied before (TG, 5.2 +/- 1.2 mmol l-1; mean +/- SEM) and after therapy (TG, 2.1 +/- 0.3 mmol l-1) with either simvastatin (n = 4) or combined therapy with gemfibrozil (n = 2). The postprandial changes of apo B100 and apo B48 were studied after a single oral fat meal (24 h; 50 gram fat m-2). Changes in triglyceride rich particles (TRP; d < 1.006 g ml-1) and remnant fractions (REM; d:1.006-1.019 g ml-1) of apo B were quantitated by scanning silverstained SDS-PAGE (4-15%). Apo B48 in fasting TRP in untreated and treated FCH was 15% and 14% of total apo B, and 6% in controls (P < 0.05). In controls, postprandial B48 increased maximally at 4 h by 81% in TRP and by 137% in REM compared to baseline. In treated FCH, the postprandial apo B48 pattern normalized in TRP compared to the untreated state. Postprandial apo B100 in controls decreased in TRP and REM by 33% and 18% (P < 0.05). In untreated and treated FCH, postprandial apo B100 remained unchanged vs. baseline in TRP and in REM suggesting hypersecretion of VLDL. The elimination of B100--assessed as area under the curve--in TRP (32.5 +/- 3.6 au.h; mean +/- SEM) and REM fractions (33.2 +/- 3.1 au.h), improved significantly after treatment (21.0 +/- 2.8 and 20.4 +/- 3.3 au.h, respectively). The apo B48 clearance in TRP fractions was improved after treatment (4.3 +/- 1.4 au.h vs. 2.9 +/- 1.2 au.h; P = 0.06), but not in REM fractions (2.8 +/- 1.0 au.h vs. 1.8 +/- 0.5 au.h; NS). In conclusion, in FCH subjects with apo B100 hypersecretion and increased fasting plasma apo B48 levels, reduction of fasting plasma TG improved, but did not normalize, TRP apo B48 and B100 metabolism. However, therapy normalized postprandial apo B100 remnant metabolism. Impaired postprandial apo B metabolism may be instrumental in the development of premature atherosclerosis in FCH subjects.
家族性混合性高脂血症(FCH)中肝脏极低密度脂蛋白(VLDL)过量生成可能会延迟含致动脉粥样硬化载脂蛋白(apo)B颗粒的清除。我们研究了在6名患有FCH的男性受试者中,通过降血脂治疗使空腹血浆甘油三酯(TG)正常化是否会改善apo B48和apo B100的代谢,并将他们与6名血脂正常的对照者进行比较。FCH患者在使用辛伐他汀(n = 4)或吉非贝齐联合治疗(n = 2)前(TG,5.2±1.2 mmol l-1;均值±标准误)和治疗后(TG,2.1±0.3 mmol l-1)接受研究。在单次口服脂肪餐(24小时;50克脂肪/m²)后研究apo B100和apo B48的餐后变化。通过扫描银染SDS-PAGE(4-15%)对富含甘油三酯颗粒(TRP;d < 1.006 g/ml-1)和apo B的残余部分(REM;d:1.006-1.019 g/ml-1)的变化进行定量。未治疗和治疗后的FCH患者空腹TRP中的apo B48分别占总apo B的15%和14%,对照组为6%(P < 0.05)。在对照组中,与基线相比,餐后4小时TRP中apo B48在TRP中最大增加81%,在REM中增加137%。在治疗后的FCH患者中,与未治疗状态相比,TRP中餐后apo B48模式正常化。对照组餐后TRP和REM中的apo B100分别降低33%和18%(P < 0.05)。在未治疗和治疗后的FCH患者中,餐后TRP和REM中的apo B100与基线相比保持不变,提示VLDL分泌过多。治疗后,TRP(32.5±3.6 au.h;均值±标准误)和REM部分(33.2±3.1 au.h)中B100的清除率(以曲线下面积评估)显著改善(分别为21.0±2.8和20.4±3.3 au.h)。治疗后TRP部分中apo B48的清除率有所改善(4.3±1.4 au.h对2.9±1.2 au.h;P = 0.06),但REM部分未改善(2.8±1.0 au.h对1.8±0.5 au.h;无显著性差异)。总之,在apo B100分泌过多且空腹血浆apo B48水平升高的FCH受试者中,空腹血浆TG的降低改善了,但未使TRP中apo B48和B100的代谢正常化。然而,治疗使餐后apo B100残余代谢正常化。餐后apo B代谢受损可能在FCH受试者过早发生动脉粥样硬化中起作用。